Centessa Pharmaceuticals
CNTA
CNTA was delisted on the 23rd of June, 2026.
69 hedge funds and large institutions have $841M invested in Centessa Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 27 increasing their positions, 7 reducing their positions, and 7 closing their positions.
286% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 7
181% more call options, than puts
Call options by funds: $216K | Put options by funds: $77K
157% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 7
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
46% more capital invested
Capital invested by funds: $577M → $841M (+$264M)
19% more funds holding
Funds holding: 58 → 69 (+11)
1.95% more ownership
Funds ownership: 74.25% → 76.2% (+1.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$29.2M |
| 2 |
FLAM
First Light Asset Management
Edina,
Minnesota
|
+$28.4M |
| 3 |
5VM
5AM Venture Management
San Francisco,
California
|
+$11.8M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$7.71M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.96M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$69.8M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$6.12M |
| 3 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
-$3.52M |
| 4 |
Morgan Stanley
New York
|
-$2.75M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$1.12M |
CNTA Hedge Fund Activity: Q1 2024 in Review
69 of the 6,946 institutional investors tracked by Wall St. Rank reported a position in Centessa Pharmaceuticals (CNTA) for Q1 2024, worth a combined $841M — up 46% from $577M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new CNTA positions and 7 closed out — a net gain of 11 holders — while 27 added to existing stakes and 7 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $29.2M. The largest seller was BVF Inc, exiting entirely with an estimated $69.8M sold.
- 69 institutional investors held Centessa Pharmaceuticals (CNTA) as of Q1 2024, up from 58 in Q4 2023.
- Funds reported $841M of Centessa Pharmaceuticals stock for Q1 2024, up 46% quarter-over-quarter.
- 18 funds opened new Centessa Pharmaceuticals positions in Q1 2024 and 7 closed out, a net change of +11 holders.
- The largest Centessa Pharmaceuticals buyer in Q1 2024 was Perceptive Advisors, an estimated $29.2M added.
- The largest Centessa Pharmaceuticals seller in Q1 2024 was BVF Inc, an estimated $69.8M sold.
Based on aggregated 13F filings for Q1 2024.